Nanocurcumin formulation: a possible therapeutic agent for post COVID inflammatory syndrome

References

• Schippers MC. For the greater good? The devastating ripple effects of the covid-19 crisis. Front Psychol. 2020;11:577740.
   PubMed Web of Science ®Google Scholar
• Tran BX, Nguyen HT, Le HT, et al. Impact of COVID-19 on economic Well-Being and quality of life of the vietnamese during the national social distancing. Front Psychol. 2020;11:565153.
   PubMed Web of Science ®Google Scholar
• Porras Gallo I. The fight against "avoidable" diseases and the 1918-1919 influenza epidemic in Spain. Dynamis. 1994;14:159–183.
   PubMedGoogle Scholar
• Abou-Arab O, Bennis Y, Gauthier P, et al. Association between inflammation, angiopoietins, and disease severity in critically ill COVID-19 patients: a prospective study. Br J Anaesth. 2021;126(3):e127–e130.
   PubMed Web of Science ®Google Scholar
• Kupferschmidt K. WHO relaunches global drug trial with three new candidates. Science. 2021;373(6555):606–607.
   PubMed Web of Science ®Google Scholar
• Kandeel M, Al-Nazawi M. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease. Life Sci. 2020;251:117627.
   PubMed Web of Science ®Google Scholar
• Elavarasi A, Prasad M, Seth T, et al. Chloroquine and hydroxychloroquine for the treatment of COVID-19: a systematic review and Meta-analysis. J Gen Intern Med. 2020;35(11):3308–3314.
   PubMed Web of Science ®Google Scholar
• Singh AK, Singh A, Singh R, et al. Remdesivir in COVID-19: a critical review of pharmacology, pre-clinical and clinical studies. Diabetes Metab Syndr. 2020;14(4):641–648.
   PubMed Web of Science ®Google Scholar
• He Q, Mao Q, An C, et al. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg Microbes Infect. 2021;10(1):629–637.
   PubMed Web of Science ®Google Scholar
• Ostadgavahi AT, Booth R, Sisson G, et al. Heterologous immunization with covishield and pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response. J Infect Dev Ctries. 2021;15(5):653–656.
   PubMed Web of Science ®Google Scholar
• Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130(6):2757–2765.
   PubMed Web of Science ®Google Scholar
• Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–1589.
   PubMed Web of Science ®Google Scholar
• Ribeiro Dos Santos Miggiolaro AF, da Silva Motta Junior J, Busatta Vaz de Paula C, et al. Covid-19 cytokine storm in pulmonary tissue: anatomopathological and immunohistochemical findings. Respir Med Case Rep. 2020;31:101292.
   PubMed Web of Science ®Google Scholar
• Sanghai N, Tranmer GK. Taming the cytokine storm: repurposing montelukast for the attenuation and prophylaxis of severe COVID-19 symptoms. Drug Discov Today. 2020;25(12):2076–2079.
   PubMed Web of Science ®Google Scholar
• Song Y, Gao P, Ran T, et al. High inflammatory burden: a potential cause of myocardial injury in critically ill patients with COVID-19. Front Cardiovasc Med. 2020;7:128.
   PubMed Web of Science ®Google Scholar
• Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):11.
   PubMed Web of Science ®Google Scholar
• Miesbach W. Pathological role of angiotensin II in severe COVID-19. TH Open. 2020;4(2):e138–e144.
   PubMedGoogle Scholar
• Patra T, Meyer K, Geerling L, et al. SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells. PLoS Pathog. 2020;16(12):e1009128.
   PubMed Web of Science ®Google Scholar
• Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666–1687.
   PubMed Web of Science ®Google Scholar
• Singh TU, Parida S, Lingaraju MC, et al. Drug repurposing approach to fight COVID-19. Pharmacol Rep. 2020;72(6):1479–1508.
   PubMed Web of Science ®Google Scholar
• Thimmulappa RK, Mudnakudu-Nagaraju KK, Shivamallu C, et al. Antiviral and immunomodulatory activity of curcumin: a case for prophylactic therapy for COVID-19. Heliyon. 2021;7(2):e06350.
   PubMed Web of Science ®Google Scholar
• Deguchi A. Curcumin targets in inflammation and cancer. Endocr Metab Immune Disord Drug Targets. 2015;15(2):88–96.
   PubMed Web of Science ®Google Scholar
• Kim Y, Clifton P. Curcumin, cardiometabolic health and dementia. Int J Environ Res Public Health. 2018;15(10):2093.
   Web of Science ®Google Scholar
• Lelli D, Sahebkar A, Johnston TP, et al. Curcumin use in pulmonary diseases: state of the art and future perspectives. Pharmacol Res. 2017;115:133–148.
   PubMed Web of Science ®Google Scholar
• Mrityunjaya M, Pavithra V, Neelam R, et al. Immune-Boosting, antioxidant and anti-inflammatory food supplements targeting pathogenesis of COVID-19. Front Immunol. 2020;11:570122.
   PubMed Web of Science ®Google Scholar
• Yadav VS, Mishra KP, Singh DP, et al. Immunomodulatory effects of curcumin. Immunopharmacol Immunotoxicol. 2005;27(3):485–497.
   PubMed Web of Science ®Google Scholar
• Harris CB, Chowanadisai W, Mishchuk DO, et al. Dietary pyrroloquinoline quinone (PQQ) alters indicators of inflammation and mitochondrial-related metabolism in human subjects. J Nutr Biochem. 2013;24(12):2076–2084.
   PubMed Web of Science ®Google Scholar
• Ma W, Zhang R, Huang Z, et al. PQQ ameliorates skeletal muscle atrophy, mitophagy and fiber type transition induced by denervation via inhibition of the inflammatory signaling pathways. Ann Transl Med. 2019;7(18):440.
   PubMed Web of Science ®Google Scholar
• Nehra S, Bhardwaj V, Bansal A, et al. Nanocurcumin-pyrroloquinoline formulation prevents hypertrophy-induced pathological damage by relieving mitochondrial stress in cardiomyocytes under hypoxic conditions. Exp Mol Med. 2017;49(12):e404.
   PubMedGoogle Scholar
• Nehra S, Bhardwaj V, Bansal A, et al. Combinatorial therapy of exercise-preconditioning and nanocurcumin formulation supplementation improves cardiac adaptation under hypobaric hypoxia. J Basic Clin Physiol Pharmacol. 2017;28(5):443–453.
   PubMedGoogle Scholar
• Nehra S, Bhardwaj V, Bansal A, et al. Nanocurcumin accords protection against acute hypobaric hypoxia induced lung injury in rats. J Physiol Biochem. 2016;72(4):763–779.
   PubMed Web of Science ®Google Scholar
• Sirico D, Basso A, Reffo E, et al. Early echocardiographic and cardiac MRI findings in multisystem inflammatory syndrome in children. JCM. 2021;10(15):3360.
   Google Scholar
• Shchendrygina A, Nagel E, Puntmann VO, et al. COVID-19 myocarditis and prospective heart failure burden. Expert Rev Cardiovasc Ther. 2021;19(1):5–14.
   PubMed Web of Science ®Google Scholar
• Gauchotte G, Venard V, Segondy M, et al. SARS-Cov-2 fulminant myocarditis: an autopsy and histopathological case study. Int J Legal Med. 2021;135(2):577–581.
   PubMed Web of Science ®Google Scholar
• Garg S, Garg M, Prabhakar N, et al. Unraveling the mystery of covid-19 cytokine storm: from skin to organ systems. Dermatol Ther. 2020;33(6):e13859.
   PubMed Web of Science ®Google Scholar
• Chandrashekara S, Jaladhar P, Paramshetti S, et al. Post COVID inflammation syndrome: different manifestations caused by the virus. J Assoc Physicians India. 2020;68(12):33–34.
   PubMedGoogle Scholar
• Grennan D, Wang S. Steroid side effects. JAMA. 2019;322(3):282.
   PubMedGoogle Scholar
• Noor H, Ikram A, Rathinavel T, et al. Immunomodulatory and anti-cytokine therapeutic potential of curcumin and its derivatives for treating COVID-19 - a computational modeling. J Biomol Struct Dyn. 2021:1–16.
   PubMed Web of Science ®Google Scholar
• Valizadeh H, Abdolmohammadi-Vahid S, Danshina S, et al. Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients. Int Immunopharmacol. 2020;89(Pt B):107088.
   PubMedGoogle Scholar
• Saber-Moghaddam N, Salari S, Hejazi S, et al. Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: an open label nonrandomized clinical trial. Phytother Res. 2021;35:2616–2623.
   Web of Science ®Google Scholar
• Tahmasebi S, Saeed BQ, Temirgalieva E, et al. Nanocurcumin improves treg cell responses in patients with mild and severe SARS-CoV2. Life Sci. 2021;276:119437.
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhao M, Lin Z. Pyrroloquinoline quinone (PQQ) alleviated sepsis-induced acute liver injury, inflammation, oxidative stress and cell apoptosis by downregulating CUL3 expression. Bioengineered. 2021;12(1):2459–2468.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li J, Cao C, et al. Pyrroloquinoline quinone inhibits the production of inflammatory cytokines via the SIRT1/NF-kappaB signal pathway in weaned piglet jejunum. Food Funct. 2020;11(3):2137–2153.
   PubMed Web of Science ®Google Scholar
• Chiumello D, Busana M, Coppola S, et al. Physiological and quantitative CT-scan characterization of COVID-19 and typical ARDS: a matched cohort study. Intensive Care Med. 2020;46(12):2187–2196.
   PubMed Web of Science ®Google Scholar
• Parhar KKS, Zuege DJ, Shariff K, et al. Prone positioning for ARDS patients-tips for preparation and use during the COVID-19 pandemic. Can J Anaesth. 2021;68(4):541–545.
   PubMed Web of Science ®Google Scholar
• Bleakley C, Singh S, Garfield B, et al. Right ventricular dysfunction in critically ill COVID-19 ARDS. Int J Cardiol. 2021;327:251–258.
   PubMed Web of Science ®Google Scholar
• Lan Y, Liu W, Zhou Y. Right ventricular damage in COVID-19: association between myocardial injury and COVID-19. Front Cardiovasc Med. 2021;8:606318.
   PubMed Web of Science ®Google Scholar
• Szekely Y, Lichter Y, Taieb P, et al. Spectrum of cardiac manifestations in COVID-19: a systematic echocardiographic study. Circulation. 2020;142(4):342–353.
   PubMed Web of Science ®Google Scholar
• Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in wuhan, China. JAMA Cardiol. 2020;5(7):802–810.
   PubMed Web of Science ®Google Scholar
• Kelly RP, Ting CT, Yang TM, et al. Effective arterial elastance as index of arterial vascular load in humans. Circulation. 1992;86(2):513–521.
   PubMed Web of Science ®Google Scholar
• Scheel KW, Williams SE, Parker JB. Coronary sinus pressure has a direct effect on gradient for coronary perfusion. Am J Physiol. 1990;258(6 Pt 2):H1739–44.
   PubMedGoogle Scholar
• Pagnesi M, Baldetti L, Beneduce A, et al. Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19. Heart. 2020;106(17):1324–1331.
   PubMed Web of Science ®Google Scholar
• Moody WE, Mahmoud-Elsayed HM, Senior J, et al. Impact of right ventricular dysfunction on mortality in patients hospitalized with COVID-19, according to race. CJC Open. 2021;3(1):91–100.
   PubMedGoogle Scholar
• Zhao YH, Zhao L, Yang XC, et al. Cardiovascular complications of SARS-CoV-2 infection (COVID-19): a systematic review and Meta-analysis. Rev Cardiovasc Med. 2021;22(1):159–165.
   PubMed Web of Science ®Google Scholar
• Alzahrani SH, Al-Rabia MW. Cardiac injury biomarkers and the risk of death in patients with COVID-19: a systematic review and Meta-Analysis. Cardiol Res Pract. 2021;2021:1–10.
   Web of Science ®Google Scholar
• Aikawa T, Takagi H, Ishikawa K, et al. Myocardial injury characterized by elevated cardiac troponin and in-hospital mortality of COVID-19: an insight from a Meta-analysis. J Med Virol. 2021;93(1):51–55.
   PubMed Web of Science ®Google Scholar
• Wibowo A, Pranata R, Akbar MR, et al. Prognostic performance of troponin in COVID-19: a diagnostic Meta-analysis and Meta-regression. Int J Infect Dis. 2021;105:312–318.
   PubMed Web of Science ®Google Scholar
• Sheth A, Modi M, Dawson D, et al. Prognostic value of cardiac biomarkers in COVID-19 infection. Sci Rep. 2021;11(1):4930.
   PubMed Web of Science ®Google Scholar
• Tong Y, Xie Z, Li Y, et al. [Cardiac presentations in severe and critical coronavirus disease 2019]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021;33(2):229–232.
   PubMedGoogle Scholar
• Fratta Pasini AM, Stranieri C, Cominacini L, et al. Potential role of antioxidant and anti-Inflammatory therapies to prevent severe SARS-Cov-2 complications. Antioxidants (Basel). 2021;10(2):272.
   PubMedGoogle Scholar